Kura Oncology Submits NDA for Ziftomenib, Aims to Address High-Need CancersKura Oncology has submitted a New Drug Application (NDA) to the FDA for Ziftomenib, a potential breakthrough treatment for cancers with high unmet needs.Kura Oncology Inc Health Care Pharmaceuticals, Biotechnology & Life Sciences AI generated 2025-05-01 3 minutes to read
